UPDATE -- Advaxis Hosts Research Reception to Review Late-Breaking AACR Abstract
March 23 2016 - 8:09AM
Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company
developing cancer immunotherapies, today announced that the company
will host a Research Reception at the American Association for
Cancer Research (AACR) Annual Meeting. The Research Reception, for
which registration is required, will be held at 6:30 PM CT on April
18, 2016 at the Sheraton New Orleans Hotel in New Orleans,
Louisiana.
The Advaxis Research Reception will feature two
presentations:
- Lm Immunotherapy: Impact within the Tumor Microenvironment
- A review of the late-breaking poster presentation (Abstract
#LB-095) on the immunogenicity of Advaxis’ lead immunotherapy
candidate, axalimogene filolisbac, as preoperative treatment prior
to robotic-assisted surgery in patients with HPV-associated head
and neck cancer.
- Rosemarie Krupar, MD, Baylor College of Medicine
- Immunogenicity of ADXS-HER2 in Canine Osteosarcoma
- Nicola Mason, PhD, BVetMed, Assistant Professor of Medicine,
University of Pennsylvania
- Effects of Advaxis’ Lm Immunotherapy on the STING Pathway
- Robert Petit, PhD, Chief Scientific Officer, Advaxis
- Cancer Neoepitope Immunotherapy: An Update on ADXS-NEO
- Robert Petit, PhD, Chief Scientific Officer, Advaxis
Attendees will also have the opportunity to view
the late breaking Phase 2 poster featured at AACR and ask questions
of the lead author. Space is limited and registration, which is
required, can be completed online at:
https://www.regonline.com/builder/site/Default.aspx?EventID=1824612.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a
clinical-stage biotechnology company developing multiple cancer
immunotherapies based on its proprietary Lm Technology™. The Lm
Technology™, using bioengineered live attenuated Listeria
monocytogenes (Lm) bacteria, is the only known cancer immunotherapy
agent shown in preclinical studies to both generate cancer fighting
T-cells directed against cancer antigens and neutralize Tregs and
myeloid-derived suppressor cells (MDSCs) that protect the tumor
microenvironment from immunologic attack and contribute to tumor
growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene
filolisbac, targets human papilloma virus (HPV)-associated cancers
and is in clinical trials for three potential indications: Phase 2
in invasive cervical cancer, Phase 1/2 in head and neck cancer, and
Phase 1/2 in anal cancer. The U.S. Food and Drug Administration
(FDA) has granted axalimogene filolisbac orphan drug designation
for each of these three clinical settings. Advaxis has two
additional immunotherapy products: ADXS-PSA in prostate cancer and
ADXS-HER2 in HER2 expressing solid tumors, in human clinical
development.
For additional information on Advaxis, visit
www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube
and Google+.
Forward-Looking Statements
This media statement contains forward-looking
statements, including, but not limited to: statements regarding
Advaxis’ ability to develop the next generation of cancer
immunotherapies; and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks, including the risk factors set forth
from time to time in Advaxis’ SEC filings, including but not
limited to its report on Form 10-K for the fiscal year ended
October 31, 2015, which is available at http://www.sec.gov. Advaxis
undertakes no obligation to publicly release the result of any
revision to these forward-looking statements, which may be made to
reflect the events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, except as required
by law. You are cautioned not to place undue reliance on any
forward-looking statements.
CONTACTS:
Company:Advaxis, Inc.Greg
Mayes, Executive Vice President and
COOmayes@advaxis.com609.250.7515
Media Contact:JPA Health
CommunicationsCatherine Brady Catherine@jpa.com617.945.9316
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From Apr 2024 to May 2024
Ayala Pharmaceuticals (QX) (USOTC:ADXS)
Historical Stock Chart
From May 2023 to May 2024